CTD, Inc.

March 22, 2010 08:00 ET

CTD Holdings Receives Large Order From Brazil for Trappsol Cyclo™ Which May Provide Benefit in Many Lysosomal Storage Diseases

HIGH SPRINGS, FL--(Marketwire - March 22, 2010) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) today announced that a significant order has been placed by a Brazilian healthcare organization for Trappsol Cyclo™ for the experimental treatment of Niemann Pick Type C (NPC) disease. Currently, there are approximately a dozen children in Brazil diagnosed with NPC disease, a rare genetic cholesterol transport disorder that causes severe neurological effects in infants, children and adults.

"There is no known cure for Niemann Pick Type C disease, nor is there any FDA approved treatment for this debilitating and relentlessly progressive condition," said Rick Strattan, CEO of CTD Holdings, Inc. "Trappsol Cyclo™ is showing promise in NPC afflicted experimental animals, and many international doctors treating NPC patients are expressing interest in the compound as a potential life extending therapy. Patients with the fatal condition have no other options currently."

In April 2009, Trappsol Cyclo™ was approved under compassionate use by the U.S. Food and Drug Administration (FDA) to treat Addi and Cassi Hempel, identical twin girls suffering from NPC disease. Medi-ports, similar to those used to administer chemotherapy drugs, were surgically placed into the twins' chest walls which allowed doctors to continuously infuse Trappsol Cyclo™. In March 2010, the Hempel family filed an Orphan Drug Application with the FDA for Trappsol Cyclo™ as the treatment for NPC. The family is also working with doctors to determine the most efficacious route of administration for the Trappsol Cyclo™.

"There is hope that cyclodextrin can not only help treat NPC disease, but there is solid evidence that other lysosomal storage diseases (LSD) can be treated," added Strattan.

About Niemann Pick Type C diseases
NPC disease is one of at least 42 rare, fatal diseases which are classed as lysosomal storage diseases (LSD). The disease is characterized by cellular accumulation of lipids, in particular, unesterified cholesterol and glycosphingolipids, in most cells of the body including brain, liver and spleen. Treatment with Cyclo™ has been shown to delay clinical disease onset, to reduce intraneuronal storage, secondary markers of neurodegeneration, and significantly increase lifespan in NPC mice.

About CTD Holdings, Inc.
CTD Holdings, Inc. is a one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in many diverse industries that endeavor to put non water-soluble ingredients into water-based formulations for direct use or conversion into stable, easy to use powders.

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH is timely in the filing of its SEC mandated financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.

Contact Information

  • For More Information:
    Rick Strattan
    CTD Holdings
    Email Contact